Key result
Neuroleptic-responder schizophrenic patients had significantly shorter CAG repeat alleles for the hGT1 gene compared to controls (P=0.0012).
Why the study?
Are allelic variants or expansions of CAG repeat-containing genes associated with schizophrenia or responsiveness to conventional neuroleptics?
Case-Control (n=228)
Are allelic variants or expansions of CAG repeat-containing genes associated with schizophrenia or responsiveness to conventional neuroleptics?
p-value: p=0.047
The hGT1 gene, or a gene in its vicinity, may be involved in the etiology of schizophrenia or in modifying the disease phenotype regarding neuroleptic responsiveness.
Does not implicate CAG repeats in schizophrenia or neuroleptic response; leaves open their etiologic role for future study.
Recently, it has been suggested that trinucleotide repeat-containing genes may be involved in the etiology of schizophrenia. This study was aimed at investigating putative associations between allelic variants or expansions of CAG repeat-containing genes (CAGrCG) and schizophrenia or its variability with respect to responsiveness to conventional neuroleptics. CAG repeat allelic variants of 14 expressed sequences were compared among three groups of subjects: neuroleptic-responder (R; n = 43) and neuroleptic-nonresponder (NR; n = 63) schizophrenic patients, and a control group (C; n = 122). No CAG expansions, in the range of those observed in neurodegenerative diseases, were identified in these 14 expressed sequences. The sizes of CAG repeat for the hGT1 gene were marginally different among the three groups of subjects (Kruskal-Wallis H (2, 456) = 10.48, Bonferroni corrected P = 0.047). Comparisons among the different groups indicated that neuroleptic responders have shorter alleles compared to controls (Mann-Whitney adjusted Z = −3.23, P = 0.0012). NR patients were not different from controls. These preliminary results suggest that the hGT1 gene, or a gene in its vicinity, may be involved in the etiology of schizophrenia or in modifying the disease phenotype with regard to outcome and/or neuroleptic responsiveness. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 88:694–699, 1999.
No takes yet. Share an insight, caveat, or question.
Joober et al. (1999) conducted a case-control in Schizophrenia (n=228). CAG repeat allelic variants of 14 expressed sequences (including hGT1 gene) vs. Controls was evaluated on Differences in CAG repeat sizes among groups (p=0.047). Neuroleptic-responder schizophrenic patients had significantly shorter CAG repeat alleles for the hGT1 gene compared to controls (P=0.0012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: